Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• The immune system, particularly CD8+ T cells, is crucial in fighting urothelial bladder cancer (UBC).
• Tumors employ immune escape mechanisms to evade CD8+ T cell-mediated killing.
• Understanding these mechanisms is vital for developing effective cancer immunotherapies.

Purpose of the Study:

• To investigate tumor immune escape mechanisms that suppress CD8+ T cell cytotoxicity in UBC.
• To identify specific molecular pathways involved in the downregulation of CD8+ T cell effector functions.

Main Methods:

• Analysis of CD8+ T cells from peripheral blood, sentinel nodes, and tumors in 42 UBC patients.
• Flow cytometry, RT-qPCR, and ELISA for cellular and molecular analysis.
• Mass spectrometry to identify proteins in UBC cell line supernatants and in vitro validation of signaling pathways.

Main Results:

• CD8+ T cells in sentinel nodes showed significantly reduced perforin (PRF1) expression (1.8-fold decrease) despite maintained granzyme B levels.
• Perforin-deficient CD8+ T cells exhibited an exhausted Tc2 phenotype (PD-1+, GATA-3+) and low T-bet expression.
• UBC cell-free supernatants induced perforin deficiency in CD8+ T cells, with ICAM-1 and TGFβ2 signaling identified as key mediators.

Conclusions:

• A novel UBC immune escape mechanism involves tumor-induced suppression of perforin expression in CD8+ T cells via ICAM-1 and TGFβ2.
• Targeting ICAM-1 and TGFβ2 signaling presents a potential combination strategy for UBC immunotherapy.